Join the Epclusa group to help and get support from people like you.
Epclusa News
Learn the Differences Between Hepatitis A, B, C, D & E
THURSDAY, July 6, 2023 – Curious about what the differences are between hepatitis A, B, C, D and E? If so, you’ve come to the right place. Here, experts break down hepatitis infection by type to r...
Hepatitis C Treatments: A Comprehensive Guide
THURSDAY, July 6, 2023 – Did you know the U.S. Centers for Disease Control and Prevention estimates that there were nearly 68,000 new cases of acute hepatitis C in 2020 and over 107,000 newly...
Hepatitis C Can Kill, But Too Many Can't Access the Cure
THURSDAY, June 29, 2023 – More than 2 million people in the United States have hepatitis C, but most are not getting the safe treatment that can cure the disease, public health officials said...
U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 10, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric...
FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...
FDA Approves Expanded Labeling for Epclusa (sofosbuvir/velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 1, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® ...
FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating
ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain...
FDA Approves Epclusa (sofosbuvir and velpatasvir) for Treatment of all Major Forms of Chronic Hepatitis C Virus Infection
June 28, 2016 – The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For...
Ask a question
To post your own question to this support group, sign in or create an account.